"Securing a new cornerstone investor of the calibre of Octa Phillip Bioscience Managers, plus reconfirmation of Australian Ethical Investment support, is a validation of management's strategic approach in the building of a strong market base for the ReCell technology and testament to the clinical and revenue-generating prospects of the Company over the coming years." Shareholder Purchase Plan. The SPP will be offered to shareholders recorded on the Company's share register as at 7:00pm AEST on Tuesday 4 September 2012. Each shareholder will be eligible to participate up to $15,000 at $0.12 per share. The SPP is not underwritten and is expected to be capped at $3.5 million, with Avita reserving the right to accept applications in excess of this amount. An appropriate scale-back will be applied if valid applications exceed $3.5 million. Further announcements and the offer documents relating to the SPP will be provided to shareholders shortly. Board Appointments.